Spexin Levels Are Associated with Metabolic Syndrome Components

Abstract EN

Background.

Spexin (SPX) is a novel peptide that is implicated in obesity and related energy homeostasis in animals and adult humans.

Little is known about its role in adults’ overall cardiometabolic health.

The aim of the study was to determine whether circulating levels of spexin (SPX) is associated with components of metabolic syndrome (MetS).

Methods.

The present cross-sectional study included 124 participants (41 males and 83 females; aged 42.4 ± 10.3 y) (MetS group) and 136 (21 male and 115 females; aged 33.1 ± 8.7 y) (non-MetS group).

SPX was measured using commercially available assays.

Anthropometrics were measured, and fasting serum glucose levels as well as lipid profile were quantified routinely.

MetS was screened according to common definitions.

Results.

SPX levels were significantly lower in participants with MetS vs.

non-MetS (0.18 ng/ml (0.13–0.24) vs.

0.26 ng/ml (0.17–0.50); p<0.001).

In all MetS definitions used, SPX was significantly lower in the MetS group than the non-MetS group using the WHO definition after adjustment for age and BMI.

Stratification according to sex revealed that SPX was associated with MetS only in women, and this significance was lost after adjustment for age and BMI.

Conclusions.

Lower circulating levels of SPX in adults are modestly associated with components of MetS and are sex-specific.

Further studies are necessary to determine whether SPX is associated with harder outcomes such as atherosclerosis and diabetes in the general population.